Novo Nordisk AS (WBO:NNO2) Cyclically Adjusted Revenue per Share: €5.74 (As of Mar. 2026)


WBO:NNO2 Novo Nordisk AS WBO:NNO2
71 GF Score
Price €43.59
GF Value €120.11
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Cyclically Adjusted Revenue per Share?

Novo Nordisk AS WBO:NNO2 +1.76% 71 Cyclically Adjusted Revenue per Share is €5.74 as of Mar. 2026. GuruFocus rates WBO:NNO2 with a GF Score™ of 71/100 and a GF Value™ of €120.11 (Significantly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novo Nordisk AS's adjusted revenue per share for the three months ended in Mar. 2026 was €2.912. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €5.74 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novo Nordisk AS's average Cyclically Adjusted Revenue Growth Rate was 14.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novo Nordisk AS was 16.10% per year. The lowest was 6.30% per year. And the median was 12.40% per year.

As of today (2026-07-08), Novo Nordisk AS's current stock price is €43.59. Novo Nordisk AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €5.74. Novo Nordisk AS's Cyclically Adjusted PS Ratio of today is 7.59.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk AS was 31.25. The lowest was 5.56. And the median was 10.98.


Novo Nordisk AS  (WBO:NNO2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novo Nordisk AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=43.59/5.74
=7.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk AS was 31.25. The lowest was 5.56. And the median was 10.98.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novo Nordisk AS Cyclically Adjusted Revenue per Share Related Terms


Novo Nordisk AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Cyclically Adjusted Revenue per Share Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.08 3.68 4.12 4.80 5.54

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.02 5.17 5.31 5.54 5.74

WBO:NNO2 vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted PS Ratio falls into.


WBO:NNO2
71GF Score
Novo Nordisk AS WBO:NNO2
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.912/121.6800*121.6800
=2.912

Current CPI (Mar. 2026) = 121.6800.

Novo Nordisk AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.726 100.600 0.878
201609 0.730 100.200 0.886
201612 0.790 100.300 0.958
201703 0.765 101.200 0.920
201706 0.784 101.200 0.943
201709 0.724 101.800 0.865
201712 0.764 101.300 0.918
201803 0.740 101.700 0.885
201806 0.757 102.300 0.900
201809 0.769 102.400 0.914
201812 0.828 102.100 0.987
201903 0.821 102.900 0.971
201906 0.843 102.900 0.997
201909 0.854 102.900 1.010
201912 0.918 102.900 1.086
202003 0.962 103.300 1.133
202006 0.858 103.200 1.012
202009 0.890 103.500 1.046
202012 0.929 103.400 1.093
202103 0.981 104.300 1.144
202106 0.963 105.000 1.116
202109 1.043 105.800 1.200
202112 1.124 106.600 1.283
202203 1.238 109.900 1.371
202206 1.218 113.600 1.305
202209 1.349 116.400 1.410
202212 1.429 115.900 1.500
202303 1.589 117.300 1.648
202306 1.620 116.400 1.693
202309 1.754 117.400 1.818
202312 1.975 116.700 2.059
202403 1.960 118.400 2.014
202406 2.042 118.500 2.097
202409 2.144 118.900 2.194
202412 2.579 118.900 2.639
202503 2.355 120.200 2.384
202506 2.317 120.700 2.336
202509 2.259 121.600 2.260
202512 2.382 121.200 2.391
202603 2.912 121.680 2.912

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €5.74 mean?
Novo Nordisk AS (WBO:NNO2) has a Cyclically Adjusted Revenue per Share of €5.74 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Cyclically Adjusted Revenue per Share too high?
Novo Nordisk AS's current Cyclically Adjusted Revenue per Share is €5.74. Overall, Novo Nordisk AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Novo Nordisk AS's Cyclically Adjusted Revenue per Share of €5.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Cyclically Adjusted Revenue per Share is €5.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €120.11, compared to a current price of €43.59 — trading 63.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €5.74. Novo Nordisk AS's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Cyclically Adjusted Revenue per Share is €5.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.59 is trading 63.7% below its estimated GF Value™ of €120.11. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for WBO:NNO2:

  • Cyclically Adjusted Revenue per Share: €5.74
  • GF Value™: €120.11 vs. price of €43.59 (63.7% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score

Get the complete analysis for WBO:NNO2

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.59
Price
€120.11
GF Value